[Inhibitor of thromboxane A2 synthesis as anticoagulant in hemodialysis].
Iida
N
N
Department of Nephrology, Osaka Prefectural Hospital.
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001778:Blood Coagulation Disorders / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors; D004285:Dogs; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D006801:Humans; D008689:Methacrylates / Q000494:pharmacology; D010740:Phospholipases / Q000037:antagonists & inhibitors; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D017482:Receptors, Thromboxane; D006435:Renal Dialysis / Q000009:adverse effects*; D013442:Sulfinpyrazone / Q000494:pharmacology; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000494:pharmacology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D016861:Cyclooxygenase Inhibitors; D005229:Fatty Acids, Monounsaturated; D008689:Methacrylates; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; C037869:ONO 11120; D010740:Phospholipases; D013930:Thromboxane-A Synthase; C034364:ozagrel; D001241:Aspirin; D013442:Sulfinpyrazone; C054678:Satigrel